
Please try another search
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Name | Age | Since | Title |
---|---|---|---|
Shlomo Spokone Shalev | 63 | 2014 | Chairman |
Osnat Hillel Fain | 59 | 2015 | Independent Non-Executive & External Director |
Murray Urowitz | - | - | Member of Clinical Advisory Board |
Doron Turgeman | 57 | 2014 | Non-Executive Director |
David A. Isenberg | - | 2015 | Member of Clinical Advisory Board |
Daniel J. Wallace | - | - | Member of Clinical Advisory Board |
Lee S. Simon | 74 | - | Member of Clinical Advisory Board |
Alexander Rabinovich | 54 | 2017 | Non-Executive Director |
Simon Bowman | - | 2017 | Member of Clinical Advisory Board |
Robert I. Fox | - | 2017 | Member of Clinical Advisory Board |
Iris Shapira Yalon | 58 | 2020 | Independent Non-Executive & External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review